2193085-94-6

NCGC1481 is an inhibitor of FLT3, IRAK1, and IRAK4, with IC50 values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. NCGC1481 can effectively overcome the adaptive resistance of leukemia cells to FLT3 inhibitors and has antileukemic activity[1].

[1] Melgar K, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. DOI:10.1126/scitranslmed.aaw8828